Basilar artery remodelling in the genetically hypertensive rat: Effects of nitric oxide synthase inhibition and treatment with valsartan and enalapril

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 8, 2000, Pages 642-646

  Ledingham, J M ^a   Laverty, R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Basilar artery; Blood pressure; Enalapril; Genetic hypertension; Genetically hypertensive rats; Nitric oxide synthase inhibition; Valsartan; Ventricular hypertrophy

Indexed keywords

ENALAPRIL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MEDIA; BASILAR ARTERY; CARDIOVASCULAR EFFECT; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME INHIBITION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERTENSION; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BASILAR ARTERY; BLOOD PRESSURE; BRAIN; CEREBROVASCULAR ACCIDENT; ENALAPRIL; ENZYME INHIBITORS; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, INBRED SHR; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE; VENTRICULAR FUNCTION, LEFT;

EID: 0033948497     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03300.x     Document Type: Conference Paper

References (26)

1. 1. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl Acad. Sci. USA 1989; 86: 3375-8.
2. 2. Sarkar R, Webb RC. Does nitric oxide regulate smooth muscle cell proliferation? J. Vasc. Res. 1998; 35: 135-42.
3. ω-nitro-L-arginine methyl ester affects blood pressure and cardiovascular structure in the genetically hypertensive rat strain. Clin. Exp. Pharmacol. Physiol. 1997; 24: 433-5.
4. 4. Ledingham JM, Laverty R. Prevention of stroke in NOS-inhibited genetically hypertensive rats by treatment with valsartan and enalapril, alone and in combination with bosentan. Naunyn Schmiedebergs Arch. Pharmacol. 1998; 358 (Suppl. 1): R271 (Abstract).
5. 5. Panza JA, García CE, Kilcoyne CM, Quyyumi AA, Cannon RO. Impaired endothelium-dependent vasodilatation in patients with essential hypertension. Circulation 1995; 91: 1732-8.
6. 6. Vanhoutte PM. Endothelial dysfunction in hypertension. J. Hypertens. 1996; 14 (Suppl. 5): S83-93.
7. 7. Lüscher TF. The endothelium as a target and mediator of cardiovascular disease. Eur. J. Clin. Invest. 1993; 23: 670-85.
8. 8. Whisnant JP. Extracranial and intracranial arterial disease. Hypertens. Res. 1994; 17 (Suppl. 1): S43-6.
9. 9. Hennericio MG, Schwartz A. Hypertension related cerebral lesions: Are patterns of cerebral infarction topography of diagnostic relevance? Hypertens. Res. 1994; 17 (Suppl. 1): S33-6.
10. 10. Gundersen HJG, Bagger P, Bendtsen TF et al. The new stereological tools: Dissector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. Acta Pathol. Microbiol. Immunol. Scand. 1988; 96: 857-81.
11. 12. Sterio DC. The unbiased estimation of number and sizes of arbitrary particles using the disector. J. Microsc. 1984; 134: 127-36.
12. 13. Mulvany MJ, Baumbach GL, Alkjaer C et al. Vascular remodeling. Hypertension 1996; 28: 505-6.
13. 14. Mangiarua EI, Lee RMKW. Morphometric study of cerebral arteries from spontaneously hypertensive and stroke-prone spontaneously hypertensive rats. J. Hypertens. 1992; 10: 1183-90.
14. 15. Arribas SM, Gordon JF, Daly CJ, Dominiczak AF, McGrath JC. Confocal microscopic characterisation of a lesion in a cerebral vessel of the stroke-prone spontaneously hypertensive rat. Stroke 1996; 27: 1118-23.
15. 16. Kitazono T, Faraci F, Heistad D. L-Arginine restores dilator responses of the basilar artery to acetylcholine during chronic hypertension. Hypertension 1996; 2: 893-6.
16. 17. Blot S, Arnal J-F, Xu Y, Gray F, Michel J-B. Spinal cord infarcts during long-term inhibition of nitric oxide synthase in rats. Stroke 1994; 25: 1666-73.
17. 18. Orange SJ, Ledingham JM, Laverty R. Cardiovascular effects of chronic nitric oxide synthase inhibition in genetically hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2000; 27: 488-93.
18. 19. Winqvist RJ, Bunting PB, Baskin EP, Wallace AA. Decreased endothelium-dependent relaxation in New Zealand genetically hypertensive rats. J. Hypertens. 1984; 2: 536-41.
19. 20. Konishi M, Su C. Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. Hypertension 1983; 5: 881-6.
20. 21. Diederich D, Yang Z, Buhler FR, Luscher TF. Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am. J. Physiol. 1990; 258: H445-51.
21. 22. Lüscher TF, Vanhoatte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8: 344-8.
22. 23. Angus JA, Dyke AC, Jennings GL et al. Release of endothelium-derived relaxing factor from resistance arteries in hypertension. Kidney Int. 1992; 41 (Suppl. 37): S179-86.
23. 24. Shapiro HM, Stromberg DD, Lee DR, Weiderhielm CA. Dynamic pressures in the pial artery circulation. Am. J. Physiol. 1971; 221: 279-83.
24. 25. Faraci FM, Heistad DD, Mayhan WG. Role of large arteries in regulation of blood flow to brain stem in cats. J. Physiol. 1987; 387: 115-23.
25. 26. Faraci FM, Heistad DD. Regulation of large cerebral arteries and cerebral microvascular pressure. Circ. Res. 1990; 66: 8-17.
26. 27. Lee RMKW. Morphology of cerebral arteries. Pharmacol. Ther. 1995; 66: 149-73.